These tests are exome-sequencing-based, covering over 22,000 genes, which may increase diagnostic yields(identifying the cause of a disorder), and cover Asian-specific genes that may not be included in manymicroarray- or panel-based gene tests.

Limited by traditional testing of only tens or even hundreds of genes at a time, many patients with suspectedgenetic disorders have suffered for years without obtaining a diagnosis, a frustrating process often described asa “Diagnostic Odyssey”. Whole exome sequencing is increasingly adopted by clinicians in the U.S. to quicklyobtain a diagnosis for these “unresolved” cases. With a diagnosis, physicians can predict the course of thedisorder, provide a prognosis, and in certain cases, treat the disorder. The families, especially those withpediatric patients, can understand the genetic risks for other family members, and seek access to appropriatesupport networks.

UCLA Clinical Genomics Center is one of the first U.S. medical institutions offering clinical-grade wholeexome sequencing for diagnosis of pediatric and adult genetic disorders. Leveraging their extensive expertise indiagnosis and treatment of hereditary diseases, Rainbow Genomics is committed to helping Asian patients byresolving their clinical cases. These undiagnosed cases, especially in the pediatric area, remain as a substantialmedical burden for many local communities.

“The UCLA Clinical Genomics Center is delighted to extend our services and expertise to the Asianpopulations served by Rainbow Genomics," said Dr. Wayne Grody, Director of Molecular Diagnostics for theUCLA Health system. “While those countries have robust economies and impressive technology, they haveremained underserved in the areas of genetic testing and genomic medicine. This collaboration will go a longway toward growing these services, with benefits on both sides of the Pacific."

“Rainbow Genomics is committed to bringing evidence-based genetic tests, supported by 'actionable' findings,to patients in Asia Pacific,” Said Daniel Siu, CEO of Rainbow Genomics. “Currently, obtaining a whole exomesequencing test from a leading U.S. medical institution without insurance coverage is prohibitively expensive.The relationship between UCLA Clinical Genomics Center and Rainbow Genomics enables many middle-classfamilies to access exceptionally-high-quality exome sequencing genetic tests that may finally provide adiagnosis, something that these families have been seeking for years."

About Rainbow GenomicsRainbow Genomics is committed to providing clinically-validated and affordable genetic tests to patients inHong Kong, Japan, Singapore and other Asian countries. The company delivers clinical interpretationsspecifically for Asians, based on expert understanding of their genetics, and medical care experience in HongKong, Japan, and the United States. Rainbow Genomics specializes in providing whole exome sequencing andpharmacogenomic tests to enable physicians to use genomic information for diagnosis, treatment, and diseaseprevention. Visit us at rainbowgenomics.com.